Long Term Call For Lupin

Long Term Call For LupinStock market analyst Varun Daga has maintained 'buy' rating on Lupin Ltd stock to achieve a long term target of Rs 2010.

According to analyst, the interested investors can purchase the stock with stop loss of Rs 1785.

Today, the stock of the company opened at Rs 1881.25 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 76.61 and 24.76 respectively.

The share price has seen a 52-week high of Rs 1970 and a low of Rs 780 on BSE.

Lupin is eyeing to make acquirements in Brazilian and Mexican market with the aim to strengthen its proceeds from the Latin American zone.

Lupin has decided to invest around $50 million to $75 million on each acquisition.

Moreover, the company is in search of firms, which have a sturdy marketing affiliation with medical doctors and will make the acquirements shortly.

Lupin, on July 01, announced that US Food and Drug Administration (USFDA) has given final nod to its US arm, Lupin Pharmaceuticals for abbreviated new drug application (ANDA) for Famotidine for Oral Suspension ( 40mg/5ml).